Trial Site Detail
Drug: |
Regorafenib |
|||
|---|---|---|---|---|
Trial: |
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Recruiting |
|||
MD Anderson Cancer Center1505 Holcombe Blvd. |
Principal Investigator: |
Neeta Somaiah, MD |
|---|---|
Contact: |
713-792-3626 nsomaiah@mdanderson.org |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
MD Anderson Cancer Center Website: |
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.